PuSH - Publication Server of Helmholtz Zentrum München

Wille, K.* ; Dumke, M.* ; Wilsdorf, N.* ; Sadjadian, P.* ; Schneider, A.* ; Jender-Bartling, S.* ; Kolatzki, V.* ; Horstmann, A.* ; Meixner, R. ; Jiménez-Muñoz, M. ; Fuchs, C. ; Tischler, H.J.* ; Griesshammer, M.*

Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia.

Eur. J. Haematol., DOI: 10.1111/ejh.14302 (2024)
Publ. Version/Full Text DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
INTRODUCTION: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes. PATIENTS AND METHODS: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.0 months compared standard salvage chemotherapy (FLAG-Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG-Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy. RESULTS: Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log-rank-test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group. CONCLUSIONS: The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Flavida ; Acute Myelocytic Leukemia (aml) Leukemia ; Refractory ; Relapsed ; Venetoclax; Recommendations; Chemotherapy
ISSN (print) / ISBN 0036-553X
e-ISSN 1600-0609
Journal European Journal of Haematology
Publisher Wiley
Publishing Place 111 River St, Hoboken 07030-5774, Nj Usa
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) CF Statistical Consulting (CF-STATCON)